Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The JAK2V617F tyrosine kinase mutation has no impact on overall survival and the risk of leukemic transformation in myelofibrosis.

Medical oncology (Northwood, London, England) - 1 Dec 2012

Helbig Grzegorz, Wieczorkiewicz Agata, Woźniczka Krzysztof, Wiśniewska-Piąty Katarzyna, Rusek Anna, Kyrcz-Krzemień Sławomira

Abstract excerpt

The prevalence of JAK2V617F tyrosine kinase mutation differs between various variants of myelofibrosis with the higher detection rate for patients with post-polycythemia vera myelofibrosis (post-PV MF; 91%) if compared to primary myelofibrosis (PMF; 45%) and post-essential thrombocythemia myelofibrosis (post-ET MF; 39%). The impact of V617F point mutation and its allele burden on overall survival (OS) and the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Aged, 80 and over

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cell Transformation, Neoplastic

Share to Janus Kinase 2

Share to Leukemia

Share to Mutation

Share to Primary Myelofibrosis

Source

Identifiers

PMID: 22383244
DOI: 10.1007/s12032-012-0190-3

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The JAK2V617F tyrosine kinase mutation has no impact on overall survival and the risk of leukemic transformation in myelofibrosis.PMID 22383244Read ↗

Consequences of the JAK2V617F allele burden for the prediction of transformation into myelofibrosis from polycythemia vera and essential thrombocythemia.Semantic proximity Read ↗

Epidemiology and clinical relevance of mutations in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 359 patients of the AGIMM group.Semantic proximity Read ↗

Leukemic Transformation in Myeloproliferative Neoplasms: A Literature Review on Risk, Characteristics, and Outcome.Semantic proximity Read ↗

Blast Transformation in Myeloproliferative Neoplasms: Risk Factors, Biological Findings, and Targeted Therapeutic OptionsSemantic proximity Read ↗

Impact of JAK2V617F Mutational Status on Phenotypic Features in Essential Thrombocythemia and Primary Myelofibrosis.Semantic proximity Read ↗

A distinct molecular mutational profile and its clinical impact in essential thrombocythemia and primary myelofibrosis patients.Semantic proximity Read ↗

Allogeneic haematopoietic cell transplantation for myelofibrosis: a real-life perspective.Semantic proximity Read ↗

Validation of the WHO-defined 20% circulating blasts threshold for diagnosis of leukemic transformation in primary myelofibrosisSemantic proximity Read ↗

After 10years of JAK2V617F: Disease biology and current management strategies in polycythaemia vera.Semantic proximity Read ↗

Clinical implications of JAK2 mutations in myeloproliferative disorders.Semantic proximity Read ↗

JAK2 V617F mutation and associated chromosomal alterations in primary and secondary myelofibrosis and post-HCT outcomes.Semantic proximity Read ↗

JAK2(V617F) allele burden discriminates essential thrombocythemia from a subset of prefibrotic-stage primary myelofibrosis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.